PA8601601A1 - PDE9 INHIBITORS TO TREAT TYPE 2 DIABETES, METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE - Google Patents

PDE9 INHIBITORS TO TREAT TYPE 2 DIABETES, METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE

Info

Publication number
PA8601601A1
PA8601601A1 PA20048601601A PA8601601A PA8601601A1 PA 8601601 A1 PA8601601 A1 PA 8601601A1 PA 20048601601 A PA20048601601 A PA 20048601601A PA 8601601 A PA8601601 A PA 8601601A PA 8601601 A1 PA8601601 A1 PA 8601601A1
Authority
PA
Panama
Prior art keywords
diabetes
cardiovascular disease
metabolic syndrome
treat type
pde9 inhibitors
Prior art date
Application number
PA20048601601A
Other languages
Spanish (es)
Inventor
Michael Scott Visser
Andrew Simon Bell
Michael John Palmer
Michael Paul Deninno
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8601601A1 publication Critical patent/PA8601601A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION PROPORCIONA LOS COMPUESTOS DE FORMULA (l) LOS ESTEREOISOMEROS Y LOS PROFARMACOS DE LOS MISMOS, Y LAS SALES DE LOS COMPUESTOS, ESTEREOISOMEROS, Y PROFARMACOS FARMACEUTICAMENTE ACEPTANBLES, EN LA QUE A,P,J,X Y R10 SON COMO SE HAN DEFINIDO EN ESTA MEMORIA DESCRIPTIVA; LAS COMPOCISICIONES FARMACEUTICAS DE LOS MISMOS; Y LOS PROCEDIMIENTOS DE USO DE LOS MISMOS; Y LOS PROCEDIMIENTOS DE USO DE LAS COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTOS DE ENFERMEDADES, INCLUYENDO DIABETES, QUE INCLUYE DIABVETES TIPO 1 Y TIPO 2, HIPERGLUCEMIA, DISLIPIDEMIA, TOLERANCIA A LA GLUCOSA ALTERADA, SINDROME METABOLICO, Y/O ENFERMEDAD CARDIVASCULAR.THE INVENTION PROVIDES THE COMPOUNDS OF FORMULA (l) THE STEREOISOMERS AND THE PROPHARMS OF THE SAME, AND THE SALTS OF THE COMPOUNDS, STEREOISOMERS, AND PHARMACEUTICALLY ACCEPTABLE PROPHARMACES, IN WHICH A, P, J AS DEFINED THIS DESCRIPTIVE MEMORY; THE PHARMACEUTICAL COMPOSITIONS OF THE SAME; AND THE PROCEDURES OF USE OF THE SAME; AND THE PROCEDURES FOR USE OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES, INCLUDING DIABETES, WHICH INCLUDES TYPE 1 AND TYPE 2 DIABVETES, HYPERGLUCEMIA, DYSLIPIDEMIA, TOLERANCE TO ALTERED CELLULASOL OR SYLLABOLATE SYNDROME.

PA20048601601A 2003-04-30 2004-04-27 PDE9 INHIBITORS TO TREAT TYPE 2 DIABETES, METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE PA8601601A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46663903P 2003-04-30 2003-04-30

Publications (1)

Publication Number Publication Date
PA8601601A1 true PA8601601A1 (en) 2005-02-04

Family

ID=33551403

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048601601A PA8601601A1 (en) 2003-04-30 2004-04-27 PDE9 INHIBITORS TO TREAT TYPE 2 DIABETES, METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE

Country Status (8)

Country Link
AR (1) AR044119A1 (en)
CL (1) CL2004000901A1 (en)
GT (1) GT200400086A (en)
NL (1) NL1026091C2 (en)
PA (1) PA8601601A1 (en)
PE (1) PE20050466A1 (en)
TW (1) TW200503714A (en)
UY (1) UY28291A1 (en)

Also Published As

Publication number Publication date
UY28291A1 (en) 2004-11-30
NL1026091A1 (en) 2004-11-02
CL2004000901A1 (en) 2005-03-18
NL1026091C2 (en) 2005-05-26
TW200503714A (en) 2005-02-01
PE20050466A1 (en) 2005-06-18
AR044119A1 (en) 2005-08-24
GT200400086A (en) 2005-01-11

Similar Documents

Publication Publication Date Title
ECSP088869A (en) DERIVATIVES OF 2-PIRAZINONE FOR THE TREATMENT OF DISEASES OR CONDITIONS WHERE THE INHIBITION OF THE ACTIVITY OF NEUTROPHYLICAL ELASTASA IS BENEFICIAL
DOP2006000141A (en) OXINDOL DERIVATIVES
CR8102A (en) DERIVATIVES OF PIRAZOLO-QUINAZOLINA, PROCEDURE FOR PREPARATION AND ITS USE AS QUINASE INHIBITORS
HN2008001666A (en) ACID DERIVATIVES OF CICLOALQUILAMINO
GT200500098A (en) NEW COMPOUNDS
PA8593101A1 (en) COMPOSITIONS FOR THE TREATMENT OF ABNORMAL CELL GROWTH
PA8587101A1 (en) NEW DERIVATIVES OF DIHYDROPIRIMIDO [4,5-D] PIRIMIDINONE REPLACED BY AMIINO, MANUFACTURE AND USE OF THE SAME AS PHARMACEUTICAL AGENTS
PA8623001A1 (en) SUBSTITUTED QUINOLINE COMPOUNDS
PA8575401A1 (en) DERIVATIVES OF BENZOCONDENSED HETEROARILAMIDE OF USEFUL TIENOPIRIDINS AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE SAME AND METHODS FOR USE
ECSP066643A (en) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS AS PDE 2 INHIBITORS
ECSP066990A (en) FORMULATIONS WITH CONTROLLED RELEASE OF ACTIVE PRINCIPLE CONTAINING VARDENAFILO
PA8621901A1 (en) SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES
CR9954A (en) PIRAZINE DERIVATIVES
PA8748101A1 (en) BENZOXAZOLES AND OXAZOLOPIRIDINS THAT ARE USEFUL AS INHIBITORS OF JANUS KINASES
UY30460A1 (en) THERAPEUTIC COMPOUNDS
UY30316A1 (en) SUBSTITUTED DERIVATIVES OF BENZAMIDS, NICOTINAMIDS, PROPANAMIDS, ACETAMIDS AND CARBOXAMIDS N- (2- (PIPERIDIN-1-ILMETIL) CICLOHEXIL) REPLACED, PREPARATION PROCESSES, COMPOSITIONS CONTAINING AND APPLICATIONS
HN2004000232A (en) "PIRROLO DERIVATIVES (3,4-C) PIRAZOL ACTIVE AS QUINASE INHIBITORS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM."
AR053554A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
ECSP088967A (en) MUSCARINIC RECEIVER AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA
GT200500020A (en) DERIVATIVES OF 1H-TIENO [2,3-C] PIRAZOL USEFUL AS QUINASE INHIBITORS.
UY30377A1 (en) FUSIONATED TRICYCLE INHIBITORS OF SULFONAMIDE OF GAMA-SECRETASA
PA8589601A1 (en) INDAZOL DERIVATIVES AS CRF ANTAGONISTS
DK1641454T3 (en) Pyrazolo [3,4-B] pyridin-6-ones as GSK-3 inhibitors
ECSP088966A (en) MUSCARINIC RECEIVER AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA
UY27759A1 (en) COMBINATIONS OF DRUGS CONTAINING HETEROCYCLIC COMPOUNDS AND A NEW ANTI-POLYNERGIC AGENT.